288 related articles for article (PubMed ID: 28106345)
1. Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.
Schmiegel W; Scott RJ; Dooley S; Lewis W; Meldrum CJ; Pockney P; Draganic B; Smith S; Hewitt C; Philimore H; Lucas A; Shi E; Namdarian K; Chan T; Acosta D; Ping-Chang S; Tannapfel A; Reinacher-Schick A; Uhl W; Teschendorf C; Wolters H; Stern J; Viebahn R; Friess H; Janssen KP; Nitsche U; Slotta-Huspenina J; Pohl M; Vangala D; Baraniskin A; Dockhorn-Dworniczak B; Hegewisch-Becker S; Ronga P; Edelstein DL; Jones FS; Hahn S; Fox SB
Mol Oncol; 2017 Feb; 11(2):208-219. PubMed ID: 28106345
[TBL] [Abstract][Full Text] [Related]
2. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.
Grasselli J; Elez E; Caratù G; Matito J; Santos C; Macarulla T; Vidal J; Garcia M; Viéitez JM; Paéz D; Falcó E; Lopez Lopez C; Aranda E; Jones F; Sikri V; Nuciforo P; Fasani R; Tabernero J; Montagut C; Azuara D; Dienstmann R; Salazar R; Vivancos A
Ann Oncol; 2017 Jun; 28(6):1294-1301. PubMed ID: 28368441
[TBL] [Abstract][Full Text] [Related]
3. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients.
Vidal J; Muinelo L; Dalmases A; Jones F; Edelstein D; Iglesias M; Orrillo M; Abalo A; Rodríguez C; Brozos E; Vidal Y; Candamio S; Vázquez F; Ruiz J; Guix M; Visa L; Sikri V; Albanell J; Bellosillo B; López R; Montagut C
Ann Oncol; 2017 Jun; 28(6):1325-1332. PubMed ID: 28419195
[TBL] [Abstract][Full Text] [Related]
4. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer.
García-Foncillas J; Tabernero J; Élez E; Aranda E; Benavides M; Camps C; Jantus-Lewintre E; López R; Muinelo-Romay L; Montagut C; Antón A; López G; Díaz-Rubio E; Rojo F; Vivancos A
Br J Cancer; 2018 Dec; 119(12):1464-1470. PubMed ID: 30467411
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.
Thierry AR; El Messaoudi S; Mollevi C; Raoul JL; Guimbaud R; Pezet D; Artru P; Assenat E; Borg C; Mathonnet M; De La Fouchardière C; Bouché O; Gavoille C; Fiess C; Auzemery B; Meddeb R; Lopez-Crapez E; Sanchez C; Pastor B; Ychou M
Ann Oncol; 2017 Sep; 28(9):2149-2159. PubMed ID: 28911069
[TBL] [Abstract][Full Text] [Related]
6. KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR.
Pinheiro M; Peixoto A; Rocha P; Veiga I; Pinto C; Santos C; Pinto P; Guerra J; Escudeiro C; Barbosa A; Silva J; Teixeira MR
Int J Colorectal Dis; 2022 Apr; 37(4):895-905. PubMed ID: 35303157
[TBL] [Abstract][Full Text] [Related]
7. Plasma Dynamics of RAS/RAF Mutations in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy and Anti-EGFR Treatment.
Thomsen CB; Andersen RF; Lindebjerg J; Hansen TF; Jensen LH; Jakobsen A
Clin Colorectal Cancer; 2019 Mar; 18(1):28-33.e3. PubMed ID: 30459076
[TBL] [Abstract][Full Text] [Related]
8. Blood-based
Germetaki T; Nicholls C; Adams RA; Braun M; Rogan J; Moghadam S; Lenfert E; Lukas A; Edelstein DL; Jones FS; Saunders MP
Future Oncol; 2020 Oct; 16(28):2177-2189. PubMed ID: 32716216
[No Abstract] [Full Text] [Related]
9. A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer.
Bando H; Kagawa Y; Kato T; Akagi K; Denda T; Nishina T; Komatsu Y; Oki E; Kudo T; Kumamoto H; Yamanaka T; Yoshino T
Br J Cancer; 2019 May; 120(10):982-986. PubMed ID: 31015557
[TBL] [Abstract][Full Text] [Related]
10. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
[TBL] [Abstract][Full Text] [Related]
11. Rare RAS Mutations in Metastatic Colorectal Cancer Detected During Routine RAS Genotyping Using Next Generation Sequencing.
Harlé A; Filhine-Tresarrieu P; Husson M; Boidot R; Rouyer M; Dubois C; Leroux A; Merlin JL
Target Oncol; 2016 Jun; 11(3):363-70. PubMed ID: 26661077
[TBL] [Abstract][Full Text] [Related]
12. Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR.
Gao J; Wu H; Wang L; Zhang H; Duan H; Lu J; Liang Z
BMJ Open; 2016 Jan; 6(1):e009532. PubMed ID: 26747035
[TBL] [Abstract][Full Text] [Related]
13.
Lastraioli E; Antonuzzo L; Fantechi B; Di Cerbo L; Di Costanzo A; Lavacchi D; Armenio M; Arcangeli A; Castiglione F; Messerini L; Di Costanzo F
Oncol Lett; 2021 Jan; 21(1):15. PubMed ID: 33240421
[TBL] [Abstract][Full Text] [Related]
14. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
Pietrantonio F; Vernieri C; Siravegna G; Mennitto A; Berenato R; Perrone F; Gloghini A; Tamborini E; Lonardi S; Morano F; Picciani B; Busico A; Volpi CC; Martinetti A; Battaglin F; Bossi I; Pellegrinelli A; Milione M; Cremolini C; Di Bartolomeo M; Bardelli A; de Braud F
Clin Cancer Res; 2017 May; 23(10):2414-2422. PubMed ID: 27780856
[No Abstract] [Full Text] [Related]
16. Impact of Emergent Circulating Tumor DNA
Kim TW; Peeters M; Thomas A; Gibbs P; Hool K; Zhang J; Ang AL; Bach BA; Price T
Clin Cancer Res; 2018 Nov; 24(22):5602-5609. PubMed ID: 29898991
[No Abstract] [Full Text] [Related]
17. Validation of a Multiplex Allele-Specific Polymerase Chain Reaction Assay for Detection of KRAS Gene Mutations in Formalin-Fixed, Paraffin-Embedded Tissues from Colorectal Cancer Patients.
Seekhuntod S; Thavarungkul P; Chaichanawongsaroj N
PLoS One; 2016; 11(1):e0147672. PubMed ID: 26812617
[TBL] [Abstract][Full Text] [Related]
18. Real-time PCR-based method for the rapid detection of extended RAS mutations using bridged nucleic acids in colorectal cancer.
Iida T; Mizuno Y; Kaizaki Y
Clin Chim Acta; 2019 Feb; 489():164-168. PubMed ID: 29111094
[TBL] [Abstract][Full Text] [Related]
19. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA.
Kopreski MS; Benko FA; Borys DJ; Khan A; McGarrity TJ; Gocke CD
J Natl Cancer Inst; 2000 Jun; 92(11):918-23. PubMed ID: 10841827
[TBL] [Abstract][Full Text] [Related]
20. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
